Substance Use Treatment and Recovery Team

Summary

This study is a multi-site, randomized pragmatic trial being conducted at three diverse sites. The study, called the Substance Use Treatment and Recovery Team (START), will evaluate whether a collaborative care team increases the use of two interventions-medication for opioid use disorder (MOUD), and opioid use disorder (OUD) focused discharge planning-among hospitalized patients with OUD, and improves linkage to follow-up care relative to usual care. The START consists of an addiction medicine specialist and a care manager who will use evidence-based tools to decrease barriers to MOUD and engage patients with post-discharge OUD care. A total of 414 patients will be randomized from Cedars-Sinai Medical Center in Los Angeles, the University of New Mexico Hospital in Albuquerque, and Baystate Health in Springfield, Massachusetts to receive either START or usual care, stratifying by prior MOUD exposure and site.

Conditions

• Opioid-use Disorder
• Opioid-Related Disorders

Interventions

BEHAVIORAL

Substance Use Treatment and Recovery Team (START)

START is a model of care based on Collaborative Care. START is team driven, population-focused, measurement based, and focused on promoting adoption of evidence-based interventions. The purpose of this model is to increase adoption of evidence-based interventions for opioid use disorder and to increase linkage to aftercare. The components of the START intervention are as follows: 1. Triage 2. Engage, Assess, and Plan 3. Treat 4. Communicate and Coordinate 5. Follow up 6. Monitor

Sponsors & Collaborators

• RAND

  collaborator OTHER

• University of New Mexico

  collaborator OTHER

• Baystate Health

  collaborator OTHER

• National Center for Advancing Translational Sciences (NCATS)

  collaborator NIH

• National Institute on Drug Abuse (NIDA)

  collaborator NIH

• Stanford University

  collaborator OTHER

• University of Pittsburgh

  collaborator OTHER

• Cedars-Sinai Medical Center

  lead OTHER

Principal Investigators

• Itai Danovitch, MD · Cedars-Sinai Medical Center

• Allison J Ober, PhD · RAND

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-11-11

Primary Completion

2023-12-19

Completion

2023-12-19

Countries

• United States

Study Locations